ADC Therapeutics SA 8-K

What Happened
ADC Therapeutics SA (ticker: ADCT) filed a Form 8-K on January 12, 2026 to disclose that it made an updated corporate (investor) presentation available. The presentation is attached to the filing as Exhibit 99.1. The company states this disclosure is a Regulation FD communication and is not "filed" for purposes of Section 18 of the Exchange Act nor incorporated by reference into other filings except where expressly stated.

Key Details

• Date of disclosure: January 12, 2026.
• Item reported: Regulation FD disclosure (Item 7.01); updated corporate presentation attached as Exhibit 99.1.
• Legal notice: Information in the Item and Exhibit 99.1 is not deemed filed under Section 18 of the Exchange Act and is not incorporated by reference except by specific reference.
• Filing also includes an Inline XBRL cover page (Exhibit 104).

Why It Matters
The company has publicly released updated investor materials; while the 8-K itself does not summarize the presentation contents, Exhibit 99.1 may contain updates on strategy, pipeline progress, corporate priorities, or upcoming milestones that investors should review. Retail investors who follow ADCT should read the attached presentation and any related company disclosures to assess whether there are material developments affecting the stock.